Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo followed by Secukinumab Clear all
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Upland, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

NCT00928512
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinmab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Mesa, Arizona • Peoria, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
secukinumab (AIN457), placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

NCT02159053
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Anniston, Alabama • Upland, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

NCT01649375
View directory record Official record
Conditions
Anklyosing Spondylitis
Interventions
Secukinumab (75 mg), Placebo, Secukinumab (150 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

NCT02294227
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Mesa, Arizona • Upland, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

NCT04930094
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Secukinumab 300 mg, Placebo, Secukinumab 150 mg
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982
View directory record Official record
Conditions
Chronic Plaque Type Psoriasis
Interventions
AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

NCT01989468
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038
View directory record Official record
Conditions
Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

NCT01364389
View directory record Official record
Conditions
Polymyalgia Rheumatica, Inflammatory Diseases
Interventions
AIN457, ACZ885, Prednisone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

NCT01426789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Tuscon, Arizona • Anahiem, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo, Secukinumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

NCT02696031
View directory record Official record
Conditions
Non-radiographic Spondyloarthritis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

NCT02008916
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 4, 2026, 8:30 AM EDT